Co-Authors
This is a "connection" page, showing publications co-authored by PATRICK HWU and PADMANEE SHARMA.
Connection Strength
1.098
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.148
-
Advances in the development of cancer immunotherapies. Trends Immunol. 2013 Feb; 34(2):90-8.
Score: 0.112
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.055
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.053
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.052
-
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
Score: 0.047
-
Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
Score: 0.047
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.047
-
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.043
-
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
Score: 0.043
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.043
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.041
-
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.
Score: 0.038
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.038
-
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105.
Score: 0.038
-
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
Score: 0.037
-
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016 09 05; 9(1):81.
Score: 0.037
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.036
-
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.
Score: 0.035
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.031
-
Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
Score: 0.028
-
Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
Score: 0.027
-
The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. Int J Infect Dis. 2010 Jul; 14(7):e548-52.
Score: 0.023